The use of glucose monitoring sensors is already well-established in pregnant women with type 1 diabetes (T1D), where it has been proven to improve glycemic control and perinatal outcomes. However, it has not yet been sufficiently researched in the area of gestational diabetes (GDM). Some smaller studies have shown a favorable effect on glycemic control, but no statistically significant differences were observed in reducing perinatal complications. A randomized, prospective study will include 200 pregnant women with GDM, treated at the Diabetes Outpatient Clinic of the Clinical Department of Endocrinology, Diabetes, and Metabolic Diseases at the University Medical Centre Ljubljana. Participants will be divided into two groups. The first group will measure subcutaneous glucose using FSL in addition to self-monitoring of blood glucose (SMBG) while fasting and 60 minutes after main meals at the same time intervals. In both groups, glycemic targets, maternal outcomes, and neonatal outcomes will be monitored. In the FSL + SMBG group, sensor parameters for glycemic control will also be tracked.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
205
Women with GDM in the intervention arm will use Flash Glucose Monitoring (FGM) from diagnosis until the end of pregnancy
Only using SMBG
University Medical Centre Ljubljana
Ljubljana, Slovenia
Glycemic control
Average Fasting Glucose Concentration: Measured in mmol/L, calculated from fasting blood glucose readings and average Postprandial Glucose Concentration: Measured in mmol/L, based on glucose readings taken 60 minutes after main meals.
Time frame: Up to delivery
Mean Glucose (MG) in FSL+ SMBG group
Measured in millimoles per liter (mmol/L), reflecting the average glucose level recorded by the sensor.
Time frame: Up to delivery
Mean Amplitude of Glycemic Excursions (MAGE) (FSL+SMBG group)
Measured in millimoles per liter (mmol/L), representing glycemic variability.
Time frame: Up to delivery
Time in Range - TIR (SMBG+FSL group)
Defined as the percentage (%) of time sensor glucose levels fall between 3,5 and 7,8 mmol/l
Time frame: Up to delivery
Adherence to the Intervention
Measured as the percentage (%) of completed prescribed self-monitoring and sensor glucose readings relative to the total number of prescribed measurements.
Time frame: Up to delivery
Gestational Weight Gain (GWG)
Measured in kilograms (kg), calculated as the difference between pre-pregnancy weight and the last recorded weight before delivery.
Time frame: Up to delivery
Mode of Delivery
Categorized into vaginal delivery, assisted vaginal delivery, or cesarean section, and reported as percentages (%) for each category.
Time frame: At delivery
Occurrence of Hypertensive Disorders
Reported as a binary outcome (Yes/No), based on clinical diagnosis during pregnancy.
Time frame: Up to delivery
Birth Weight
Measured in grams (g), recorded immediately after delivery
Time frame: At birth of infant
Large-for-Gestational-Age (LGA) Infant
Defined as birth weight above the 90th percentile for gestational age, reported as a binary outcome (Yes/No).
Time frame: At birth of infant
Small-for-Gestational-Age (SGA) Infant
Defined as birth weight below the 10th percentile for gestational age, reported as a binary outcome (Yes/No).
Time frame: At birth of infant
Gestational Age at Birth
Measured in completed weeks, based on the interval from the first day of the last menstrual period or ultrasound-confirmed dating.
Time frame: At birth of infant
Neonatal Hypoglycemia
Defined as blood glucose levels below 2.6 mmol/L in the first 48 hours of life, reported as a binary outcome (Yes/No).
Time frame: At birth of infant
Pregnancy loss
Miscarriage, stillbirth, neonatal death
Time frame: <28 days of life
Hyperbilirubinemia
Treated with phototherapy
Time frame: Within first 7 days of life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.